select count(*) as counts from cancer where `biomolecule` LIKE '%miRNA%' This page shows data for miRNA biomolecule.
Browse Biomarkers Based on Biomolecules
This page shows data for miRNA biomolecule.
Total Entries Retrieved: 263
ID | Biomarker | Biomolecule | Subjects | Regulation | Type | Experiment | Level of Significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
523 | hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227; | miRNA | Humans | Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1]; | Prognostic | Localised Vs Metastatic Prostate Cancer | p<0.0098 | Serum | 20473869 |
524 | miRNA-375, miRNA-141 and miRNA-200b | miRNA | Humans | Differentially Expressed | Prognostic | Pathoglical Stage pt3 vs pt2 | p<0.05 | Serum | 20473869 |
525 | miRNA-375, miRNA-141 and miRNA-200b | miRNA | Humans | Upregulated | Prognostic | Gleason Score 6 Vs Gleason Score 7 | p<0.05 | Serum | 20473869 |
526 | miRNA-375 | miRNA | Humans | Upregulated in PCa | Prognostic | Lymph Node Status: NO Vs N1 | p<0.01 | Serum | 20473869 |
527 | miRNA-141 | miRNA | Humans | Upregulated in PCa | Prognostic | Lymph Node Status: NO Vs N1 | p<0.05 | Serum | 20473869 |
528 | miRNA-141 | miRNA | Humans | Upregulated in PCa | Prognostic | Gleason Score >8 Vs Gleason Score 7 | p<0.01 | Serum | 20473869 |
529 | miRNA-375 | miRNA | Humans | Upregulated in PCa | Diagnostic | Tumor Vs Normal | p<0.001 | Tissue | 20473869 |
530 | miRNA-141 | miRNA | Humans | Upregulated in PCa | Diagnostic | Tumor Vs Normal | p<0.001 | Tissue | 20473869 |
570 | miR-874, -1274a, -1207-5p, -93, and -106a | miRNA | Humans | Upregulated in PCa | Diagnostic | Healthy Vs Prostate Cancer | miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001 | Serum | 21098088 |
571 | miR- 223, -26b, -30c, and -24 | miRNA | Humans | Downregulated in PCa | Diagnostic | Healthy Vs Prostate Cancer | miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005; | Serum | 21098088 |
572 | miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874 | miRNA | Humans | Upregulated in PCa | Diagnostic | Healthy Vs High Risk (CAPRA>5) | miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003 | Serum | 21098088 |
573 | miR-223; miR-24; | miRNA | Humans | Downregulated in PCa | Diagnostic | Healthy Vs High Risk (CAPRA>5) | miR-223 p= 0.002; miR-24 p=0.02 | Serum | 21098088 |
607 | let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93 | miRNA | Humans | Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold) | Diagnostic | Prostate Cancer Vs Normal | p<0.001 | Tissue | 21400514 |
608 | miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star | miRNA | Humans | Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold) | Diagnostic | Prostate Cancer Vs Normal | p<0.001 | Tissue | 21400514 |
609 | miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145 | Diagnostic | Prostate Cancer Vs Normal | miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001); | Tissue | 21400514 |
610 | miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146 | Diagnostic | Prostate Cancer Vs Normal | p<0.0001 | Tissue | 21400514 |
611 | miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147 | Diagnostic | Prostate Cancer Vs Normal | miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001); | Tissue | 21400514 |
612 | miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148 | Diagnostic | Prostate Cancer Vs Normal | p<0.0001 | Tissue | 21400514 |
613 | miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149 | Diagnostic | Prostate Cancer Vs Normal | miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001); | Tissue | 21400514 |
614 | miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) | miRNA | Humans | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150 | Diagnostic | Prostate Cancer Vs Normal | p<0.0001 | Tissue | 21400514 |
667 | NA | miRNA | Humans | Downregulated in Bone Metastatis: | Prognostic | Primary vs Bone Metastatis | p<0.05 | Tissue | 21647377 |
668 | NA | miRNA | Humans | Upregulated in Bone Metastatis: | Prognostic | Primary vs Bone Metastatis | p<0.05 | Tissue | 21647377 |
669 | miR-143 | miRNA | Humans | Downregulated in Bone Metastatis: 12.9 fold | Prognostic | Primary vs Bone Metastatis | p=0.012 | Tissue | 21647377 |
670 | miR-145 | miRNA | Humans | Downregulated in Bone Metastatis: 17.3 fold | Prognostic | Primary vs Bone Metastatis | p=0.014 | Tissue | 21647377 |
671 | miR-143 | miRNA | Humans | Downregulated in Bone Metastatis | Prognostic | Bone Metastatis Vs No Bone Metastasis | p=0.039 | Tissue | 21647377 |
672 | miR-145 | miRNA | Humans | Downregulated in Bone Metastatis | Prognostic | Bone Metastatis Vs No Bone Metastasis | p=0.041 | Tissue | 21647377 |
679 | miR-141 | miRNA | Humans | Upregulated with increasing PSA | Prognostic | progression Vs No Progression | p<0.001 | Plasma | 21723797 |
685 | miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940 | miRNA | Humans | Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] | Diagnostic | Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) | p= 0.0046 | Tissue | 21765474 |
686 | miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941 | miRNA | Humans | Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] | Diagnostic | Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) | p= 0.0046 | Tissue | 21765474 |
687 | miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 | miRNA | Humans | NA | Prognostic | group I (good prognosis) from group II (poor prognosis) | p=0.0005 | Tissue | 21765474 |
770 | miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p | miRNA | Humans | Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] | Prognostic | Metastatic Vs Non Metastatic | p<0.001 | Tissue | 21980368 |
771 | miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p | miRNA | Humans | Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] | Prognostic | Metastatic Vs Non Metastatic | p<0.001 | Tissue | 21980368 |
795 | mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887 | miRNA | Mice | Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215] | Diagnostic | TRAMP and wild-type (WT) littermate control mice | p≤ 0.05 | Serum | 22052531 |
796 | hsa-mir-141; hsa-mir-298; hsa-mir-375 | miRNA | Humans | Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375] | Diagnostic | Normal Vs Primary Tumor | p≤ 0.05 | Serum | 22052531 |
797 | hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375 | miRNA | Humans | Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375] | Diagnostic | Normal Vs Metastatic Tumor | p≤ 0.05 | Serum | 22052531 |
798 | hsa-mir-375 | miRNA | Humans | High expression associated with an increased risk of BCR | Prognostic | Biochemical Recurrenece | p = 0.002 | Serum | 22052531 |
799 | hsa-mir-375 | miRNA | Humans | High expression with reduced chances of relapse free survival | Prognostic | Biochemical Recurrenece | Univariate: p=0.0001; Multivariate: p=0.0260 | Serum | 22052531 |
815 | miRNA - 221 and miRNA-222 | miRNA | Humans | Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2) | Prognostic | Agressive Vs Non - Agressive Prostate Cancer | p=0.001 | Tissue | 22117988 |
837 | mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625; | miRNA | Humans | Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)] | Diagnostic | Normal Vs prostate cancer | p<0.001 | Plasma | 22240788 |
838 | mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625; | miRNA | Humans | Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)] | Diagnostic | Normal Vs localised prostate cancer | p<0.001 | Plasma | 22240788 |
839 | mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b | miRNA | Humans | Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)] | Diagnostic | metastatic prostate cancer Vs localised prostate cancer | p<0.001 | Plasma | 22240788 |
840 | miRNA - 107 | miRNA | Humans | Upregulated in Pca | Diagnostic | Benign Vs Prostate Cancer | p=0.001 | Urine | 22240788 |
841 | miRNA - 574-3p | miRNA | Humans | Upregulated in PCa | Diagnostic | Benign Vs Prostate Cancer | p=0.012 | Urine | 22240788 |
843 | let-7c + let-7e+miR30c+ miR-622+ miR1285 | miRNA | Humans | Differentially expressed | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | p<0.001 | Plasma | 22298030 |
844 | let-7c + let-7e+miR30c+ miR-622+ miR1285 | miRNA | Humans | Differentially expressed | Diagnostic | Prostate Cancer Vs Healthy Men | p<0.001 | Plasma | 22298030 |
845 | let-7c | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Men | Testing: p<0.001 | Plasma | 22298030 |
846 | let-7e | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Men | Testing: p<0.001 | Plasma | 22298030 |
847 | miR-30c | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Men | Testing: p<0.001 | Plasma | 22298030 |
848 | miR-622 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Men | Testing: p<0.001 | Plasma | 22298030 |
849 | miR-1285 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Men | Testing: p=0.0047 | Plasma | 22298030 |
850 | let-7c | miRNA | Humans | Downregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training & Testing: p<0.0001 | Plasma | 22298030 |
851 | let-7e | miRNA | Humans | Downregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p=0.0029; Testing = p<0.0001 | Plasma | 22298030 |
852 | miR-25 | miRNA | Humans | Downregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p<0.0001; Not significant in validation set | Plasma | 22298030 |
853 | miR-30c | miRNA | Humans | Downregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p<0.0001 | Plasma | 22298030 |
854 | miR-346 | miRNA | Humans | Upregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p<0.0001; Not significant in validation set | Plasma | 22298030 |
855 | miR-622 | miRNA | Humans | Upregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p<0.0001 | Plasma | 22298030 |
856 | miR-940 | miRNA | Humans | Upregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p= 0.0062 | Plasma | 22298030 |
857 | miR-1285 | miRNA | Humans | Upregulated in PCa | Diagnostic | prostate cancer Vs benign prostatic hyperplasia | Training: p<0.0001 | Plasma | 22298030 |
885 | miR145; miR221; | miRNA | Humans | Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);] | Diagnostic | Metastatic Vs Normal | p<0.01 | Tissue | 22371711 |
886 | miR143; miR145; miR221; | miRNA | Humans | Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);] | Diagnostic | Metastatic Vs Primary | p<0.04 | Tissue | 22371711 |
969 | hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 | miRNA | Humans | Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] | Prognostic | LowRisk(LR) Vs Metastatic CRPC | p<0.0001 | Serum | 22887127 |
970 | miR-375; miR-141; miR-378*; | miRNA | Humans | Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] | Prognostic | Normal Vs Primary Tumor | p<0.0001 | Tissue | 22887127 |
971 | miR-375; miR-141; miR-378*; miR-409-3p | miRNA | Humans | Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] | Prognostic | Normal Vs Low Risk Prostate Cancer | miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] | Tissue | 22887127 |
1029 | miR-30d | miRNA | Humans | Upregulated in PCa Cell Lines (> 2 fold) | Diagnostic | Normal Vs Cancerous Prostate Cell Lines | p<0.05 | Cell Lines | 23231923 |
1030 | miR-30d | miRNA | Humans | Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)] | Diagnostic | Cancerous Vs Cancer Adjacent from Same patient | p = 0.03 | Tissue | 23231923 |
1031 | miR-30d | miRNA | Humans | Shorter Survival Time in High miRNA-30d group | Prognostic | Biochemical Recurrence | p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) | Tissue | 23231923 |
1064 | miR-141 | miRNA | Humans | Upregulated in Bone Metastasis | Prognostic | Patients with Bone Metastasis Vs No Bone Metastasis | p<0.001 | Serum | 23377530 |
1085 | miR-183 | miRNA | Humans | Upregulated in PC Cells | Diagnostic | Prostate Cancer Cell Lines Vs Normal Prostate Cell Lines | p<0.05 | Cell Lines | 23538390 |
1086 | miR-183 | miRNA | Humans | Upregulated in Prostate Cancer | Diagnostic | prostate tumour Vs adjacent normal tissues | p<0.05 | Tissue | 23538390 |
1087 | miR-183 | miRNA | Humans | Upregulated in Prostate Cancer | Prognostic | Tumor Stage pT2 Vs pT3 | p<0.05 | Tissue | 23538390 |
1088 | miR-183 | miRNA | Humans | Upregulated in Prostate Cancer | Prognostic | Overall Survival | p<0.05 | Tissue | 23538390 |
1091 | miR-141 | miRNA | Humans | Upregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1092 | miR-375 | miRNA | Humans | Upregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1093 | miR-151-3p | miRNA | Humans | Upregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1094 | miR-126 | miRNA | Humans | Upregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1095 | miR-16 | miRNA | Humans | Downregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1096 | miR-205 | miRNA | Humans | Downregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1097 | PSA + miR141 + mir-151-3p + mir-16 | miRNA | Humans | Upregulated in metastatic castration-resistant PCa (mCRPC) | Prognostic | localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) | p < 0.001 | Plasma | 23574937 |
1098 | miR-423-3p | miRNA | Humans | Upregulated with High Gleason Score | Prognostic | Gleason Score < 7 Vs Gleason Score ≥ 8 | p = 0.002 | Plasma | 23574937 |
1099 | miR-205 | miRNA | Humans | Downregulated with High Gleason Score | Prognostic | Gleason Score < 7 Vs Gleason Score ≥ 8 | p = 0.004 | Plasma | 23574937 |
1100 | miR-205 | miRNA | Humans | Upregulated in Biochemical Recurrence | Prognostic | Biochemical recurrence | p = 0.006 | Plasma | 23574937 |
1101 | miR-423-3p | miRNA | Humans | Downregulated in Biochemical Recurrence | Prognostic | Biochemical recurrence | p<0.001 | Plasma | 23574937 |
1102 | miR-151-3p | miRNA | Humans | Downregulated in Biochemical Recurrence | Prognostic | Biochemical recurrence | p<0.001 | Plasma | 23574937 |
1123 | miR-24 | miRNA | Mice | Upregulated in TRAMP Mice | Diagnostic | TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice | p < 0.01 | Serum | 23719956 |
1140 | hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372 | miRNA | Humans | Upregulated with fold change > 2 | Diagnostic | prostate tumor Vs normal epithelium | p<0.05 | Tissue | 23781281 |
1141 | let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 | miRNA | Humans | Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] | Prognostic | Clinical progression free survival (CPFS) Vs. clinical failure (CF) | p<0.05 | Tissue | 23798998 |
1142 | let-7a; let-7b; let-7c | miRNA | Humans | Downregulated in PCa: [let-7a; let-7b; let-7c] | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.01 | Tissue | 23798998 |
1170 | miR-141 | miRNA | Humans | Upregulated in patients with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.007 | Serum | 23846169 |
1171 | miR-146b-3p | miRNA | Humans | Upregulated in patients with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.008 | Serum | 23846169 |
1172 | miR-194 | miRNA | Humans | Upregulated in patients with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.044 | Serum | 23846169 |
1173 | miR-146b-3p | miRNA | Humans | Upregulated in patients with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.02 | Serum | 23846169 |
1174 | miR-194 | miRNA | Humans | Upregulated in patients with Biochemical Recurrence | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p = 0.029 | Serum | 23846169 |
1199 | miR-210 | miRNA | Humans | Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold] | Diagnostic | Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) | p=0.022 | Serum | 23935962 |
1200 | miR-141 | miRNA | Humans | Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold] | Diagnostic | Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) | Training: p<0.0001; Testing: p<0.001 | Serum | 23935962 |
1201 | miR-200a | miRNA | Humans | Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold] | Diagnostic | Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) | Training: p=0.007; Testing: p=NS | Serum | 23935962 |
1202 | miR-200c | miRNA | Humans | Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold] | Diagnostic | Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) | Training: p=0.017; Testing: p=NS | Serum | 23935962 |
1203 | miR-375 | miRNA | Humans | Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold] | Diagnostic | Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) | Training: p=0.009; Testing: p=0.021 | Serum | 23935962 |
1204 | hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c; | miRNA | Humans | Upregulated in PCa (log Fold Change): [] | Diagnostic | Cancer Vs Benign | p < 0.0401 | Tissue | 23984644 |
1205 | hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96; | miRNA | Humans | Downregulated in PCa (log Fold Change): [] | Diagnostic | Cancer Vs Benign | p < 0.0401 | Tissue | 23984644 |
1224 | hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a; | miRNA | Humans | miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p ≤ 0.046 | Tissue | 24167554 |
1225 | miR-205 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.0001 | Tissue | 24167554 |
1226 | miR-214 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.0001 | Tissue | 24167554 |
1227 | miR-221 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.001 | Tissue | 24167554 |
1228 | miR-99b | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.0001 | Tissue | 24167554 |
1229 | miR-205 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Controls | p<0.001 | Urine | 24167554 |
1230 | miR-214 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Controls | p<0.001 | Urine | 24167554 |
1231 | miR-205+ miR-214 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Healthy Controls | p<0.001 | Urine | 24167554 |
1321 | miR-25; miR-101;miR-628-5p | miRNA | Humans | Differentially Expressed | Diagnostic | African Americans Vs Caucasian Americans with PCa | p<0.05 | Serum | 24477576 |
1322 | miR-25 | miRNA | Humans | Downregulated in PCa | Diagnostic | African Americans Vs Caucasian Americans with PCa | p= 0.0109 | Serum | 24477576 |
1323 | miR-101 | miRNA | Humans | Downregulated in PCa | Diagnostic | African Americans Vs Caucasian Americans with PCa | p= 0.0006 | Serum | 24477576 |
1324 | miR-628-5p | miRNA | Humans | Downregulated in PCa | Diagnostic | African Americans Vs Caucasian Americans with PCa | p<0.0001 | Serum | 24477576 |
1333 | U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p; | miRNA | Humans | Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 24518785 |
1334 | miR-182 | miRNA | Humans | Upregulated in PCa (4.7 fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | 0.717 | Tissue | 24518785 |
1335 | miR-187 | miRNA | Humans | Downregulated in PCa (12 fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | 0.052 | Tissue | 24518785 |
1336 | PSA+PCA3+miR-187 | miRNA | Humans | Downregulated in PCa (12 fold) | Diagnostic | Prostate Cancer Vs Normal Prostate | p<0.05 | Tissue | 24518785 |
1339 | miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-483-5p; miR-486-3p; miR-563; miR-940; | miRNA | Humans | Downregulated in PCa: miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-486-3p; miR-563; miR-940; Upregulated in PCa: miR-483-5p | Diagnostic | Prostate Cancer Vs Healthy Controls | p<0.01 | Urine | 24563673 |
1340 | miR-1825 | miRNA | Humans | Downregulated in PCa vs BPH vs Healthy | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.01 | Urine | 24563673 |
1341 | miR-484 | miRNA | Humans | Downregulated in PCa vs BPH vs Healthy | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.01 | Urine | 24563673 |
1342 | miR-1825 + miR-484 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.01 | Urine | 24563673 |
1343 | miR-1825 + miR-484 + PSA | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p<0.01 | Urine | 24563673 |
1351 | miR-221 | miRNA | Humans | Downregulation in high-risk prostate cancer | Prognostic | Cancer Related Death Vs No Cancer Related Death | p<0.0001 | Tissue | 24607843 |
1370 | hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b; | miRNA | Humans | NA | Prognostic | High Vs Intermediate Vs Low risk | p<0.05 | Blood | 24661838 |
1382 | miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429 | miRNA | Humans | Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429] | Prognostic | PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines) | p≤0.001 | Cell Lines | 24714754 |
1383 | miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p; | miRNA | Humans | Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;] | Prognostic | DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines) | p≤0.001 | Cell Lines | 24714754 |
1384 | mir-200c | miRNA | Humans | Upregulated in Non Responders (Median NR/median R): 1.6 fold | Predictive | PSA responder Vs Non Responder (Pre Docetaxel levels) | p=0.02 | Blood | 24714754 |
1385 | mir-200b | miRNA | Humans | Upregulated in Non Responders (Median NR/median R): 2.7 fold | Predictive | PSA responder Vs Non Responder (Pre Docetaxel levels) | p=0.02 | Blood | 24714754 |
1386 | mir-146a | miRNA | Humans | Downregulated in Non Responders (Median NR/median R): 1.4 fold | Predictive | PSA responder Vs Non Responder (Pre Docetaxel levels) | p=0.05 | Blood | 24714754 |
1387 | mir-222 | miRNA | Humans | Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold) | Predictive | PSA responder Vs Non Responder -Post Docetaxel Change | p=0.01 | Blood | 24714754 |
1388 | mir-301b | miRNA | Humans | Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold) | Predictive | PSA responder Vs Non Responder -Post Docetaxel Change | p=0.04 | Blood | 24714754 |
1389 | mir-20a | miRNA | Humans | Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold) | Predictive | PSA responder Vs Non Responder -Post Docetaxel Change | p=0.04 | Blood | 24714754 |
1390 | mir-200c + mir-200b + mir-146a | miRNA | Humans | NA | Predictive | PSA responder Vs Non Responder (Pre Docetaxel levels) | p=0.001 | Blood | 24714754 |
1391 | mir-222 + mir-301b + mir-20a | miRNA | Humans | NA | Predictive | PSA responder Vs Non Responder -Post Docetaxel Change | p = 0.02 | Blood | 24714754 |
1392 | mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a | miRNA | Humans | NA | Predictive | PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes) | p=0.001 | Blood | 24714754 |
1396 | miR-224 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Non Malignant | p=0.000628 | Tissue | 24737792 |
1397 | miR-452 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Non Malignant | p=0.000494 | Tissue | 24737792 |
1398 | Methylation status of GABRE + miR-224 +miR-452 | miRNA + Methylation | Humans | Hypermethylated in PCa | Diagnostic | Prostate Cancer Vs Non Malignant | p=0.001 | Tissue | 24737792 |
1399 | Methylation status of GABRE + miR-224 +miR-452 (as continous value ) | miRNA + Methylation | Humans | Hypermethylated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 | Tissue | 24737792 |
1400 | Methylation status of GABRE + miR-224 +miR-452 (High vs. Low ) | miRNA + Methylation | Humans | Hypermethylated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 | Tissue | 24737792 |
1401 | GABRE + miR-224 +miR-452 | mRNA + miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1403 | miR-224 | miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1404 | miR-452 | miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1406 | GABRE + miR-224 +miR-452+OAZ2 | mRNA + miRNA | Humans | Downregulated in PCa | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.001 | Tissue | 24737792 |
1424 | miR-7; miR-221; miR-222 | miRNA | Humans | Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)] | Prognostic | LNCaP Cell Lines Vs PC-3 Cell Lines | p<0.05 | Cell Lines | 24760272 |
1425 | miR-7; miR-221; | miRNA | Humans | Upregulated in Early Castration Resistant Acquisition | Prognostic | Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months) | miR-7: p=0.034; miR-221: p=0.036; | Blood | 24760272 |
1429 | miR-19a | miRNA | Humans | Upregulated in Cases | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1430 | miR-19b | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1431 | miR-345 | miRNA | Humans | Downregulated in Cases | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1432 | miR-519c-5p | miRNA | Humans | Downregulated in Cases | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1433 | miR-19a | miRNA | Humans | Upregulated in Cases | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1434 | miR-19b | miRNA | Humans | Upregulated in Cases | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1435 | miR-345 | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1436 | miR-519c-5p | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1437 | miR_19a+ miR_345+ miR_519c_5p | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1438 | miR_19b+miR_345+ miR_519c_5p | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1439 | miR_19a + miR_19b + miR_345 + miR_519c_5p | miRNA | Humans | NA | Prognostic | Gleason Score ≥7 or Gleason Score =6 | p<0.05 | Tissue | 24893170 |
1445 | miR-1 | miRNA | Humans | Downregulated in Recurrent PCa | Prognostic | Recurrence Vs No Recurrence | p = 0.036 | Tissue | 24967583 |
1446 | miR-133b | miRNA | Humans | Downregulated in Recurrent PCa | Prognostic | Recurrence Vs No Recurrence | p = 0.012 | Tissue | 24967583 |
1447 | miR-1 + miR-133b | miRNA | Humans | Downregulated in Recurrent PCa | Prognostic | Recurrence Vs No Recurrence | p = 0.012 | Tissue | 24967583 |
1448 | miR-361-3p | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p=0.004 | Prostate Secretion Samples | 24976077 |
1449 | mir-221 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p=0.03 | Prostate Secretion Samples | 24976077 |
1450 | mir-203 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p= 0.0002 | Prostate Secretion Samples | 24976077 |
1451 | mir-133b | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | p < 0.01 | Prostate Secretion Samples | 24976077 |
1452 | miR-361-3p + miR-361-3p+ mir-221+ mir-203 + mir-133b | miRNA | Humans | Downregulated in PCa [miR-361-3p; miR-361-3p; mir-221; mir-133b]; Upregulated in PCa: [mir-203] | Diagnostic | Prostate Cancer Vs Benign Prostatic Hyperplasia | NA | Prostate Secretion Samples | 24976077 |
1469 | miR-135a | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer And Adjacent Normal | p<0.0001 | Tissue | 25065599 |
1470 | miR-135a | miRNA | Humans | Downregulated in GS ≥ 8 | Prognostic | Glesaon Score ≥ 8 and Gleason Score <8 | p<0.01 | Tissue | 25065599 |
1471 | miR-135a | miRNA | Humans | Downregulated in Stage pT3a | Prognostic | Stage pT3a Vs Stage pT2c | p<0.05 | Tissue | 25065599 |
1479 | miR-30c | miRNA | Humans | Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022) | Diagnostic | Benign Vs Malignant | p=0.014 | Tissue | 25075250 |
1480 | miR-219 | miRNA | Humans | Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019) | Diagnostic | Benign Vs Malignant | p=0.004 | Tissue | 25075250 |
1481 | miR-21 | miRNA | Humans | Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) | Prognostic | Gleason Score ≥ 8 Vs Gleason Score < 8 | p=0.004 | Tissue | 25075250 |
1482 | miR-21 | miRNA | Humans | Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027) | Prognostic | Metastatic Vs Non Metastatic Prostate Cancer | p<0.0001 | Tissue | 25075250 |
1483 | miR-30c | miRNA | Humans | Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032) | Prognostic | Metastatic Vs Non Metastatic Prostate Cancer | p= 0.0003 | Tissue | 25075250 |
1484 | miR-219 | miRNA | Humans | Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) | Prognostic | Metastatic Vs Non Metastatic Prostate Cancer | p= 0.039 | Tissue | 25075250 |
1485 | miR-21 | miRNA | Humans | Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03) | Prognostic | Survival Vs No Survival | p= 0.009 | Tissue | 25075250 |
1486 | miR-30c | miRNA | Humans | Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028) | Prognostic | Survival Vs No Survival | p= 0.024 | Tissue | 25075250 |
1487 | miR-30c | miRNA | Humans | Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051) | Prognostic | PSA Recurrence Vs No Recurrence | p= 0.003 | Tissue | 25075250 |
1488 | let-7c | miRNA | Humans | Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06) | Prognostic | PSA Recurrence Vs No Recurrence | p=0.0266 | Tissue | 25075250 |
1492 | mir-23b | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.0001 | Tissue | 25115396 |
1493 | mir-27b | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.0001 | Tissue | 25115396 |
1494 | mir-24-1 | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.0001 | Tissue | 25115396 |
1495 | mir-27b | miRNA | Humans | Decreased in patients with shorter progression free interval | Prognostic | Progression Vs No Progression | p=0.0346 | Tissue | 25115396 |
1496 | miR-1290 | miRNA | Humans | NA | Prognostic | High Risk vs Low Risk (Survival) | p<0.0008 | Plasma | 25129854 |
1497 | miR-1246 | miRNA | Humans | NA | Prognostic | High Risk vs Low Risk (Survival) | p<0.0008 | Plasma | 25129854 |
1498 | miR-375 | miRNA | Humans | NA | Prognostic | High Risk vs Low Risk (Survival) | p<0.0008 | Plasma | 25129854 |
1499 | miR-1290 + miR-375 + PSA + ADT | miRNA | Humans | NA | Prognostic | High Risk vs Low Risk (Survival) | p= 0.0016 | Plasma | 25129854 |
1500 | miR-1290 + miR-375 | miRNA | Humans | NA | Prognostic | High Risk vs Low Risk (Survival) | p<0.05 | Plasma | 25129854 |
1534 | miRNA-21 | miRNA | Humans | Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6) | Diagnostic | Prostata Cancer Vs Benign prostatic hyperplasia | p=0.003 | Serum | 25190021 |
1535 | miRNA-221 | miRNA | Humans | Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6) | Diagnostic | Prostata Cancer Vs Benign prostatic hyperplasia | p=0.004 | Serum | 25190021 |
1553 | miR-221 | miRNA | Humans | Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46) | Prognostic | Recurrence Vs No Recurrence | Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05 | Tissue | 25252191 |
1554 | miR-21 | miRNA | Humans | Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54) | Prognostic | Recurrence Vs No Recurrence | p=0.0149 | Tissue | 25252191 |
1555 | miR-141 | miRNA | Humans | Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81) | Prognostic | Recurrence Vs No Recurrence | p<0.0001 | Tissue | 25252191 |
1592 | miRNA-483-5p | miRNA | Humans | Upregulated in PCa | Diagnostic | Benign Vs Malignant | p=0.013 | Urine | 25445383 |
1593 | miRNA-483-5p+ PSA | miRNA | Humans | Upregulated in PCa | Diagnostic | Benign Vs Malignant | p=0.013 | Urine | 25445383 |
1605 | letâ€7c | miRNA | Humans | Downregulated in PCa (log 2 fold change: 0.7140) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 31045265 |
1606 | mir-145 | miRNA | Humans | Downregulated in PCa (log 2 fold change: 0.4020) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 31045265 |
1607 | mir-221 | miRNA | Humans | Downregulated in PCa (log 2 fold change: 0.5174) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 31045265 |
1608 | mir-21 | miRNA | Humans | Upregulated in PCa (log 2 fold change: 0.6068) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 31045265 |
1609 | mir-182 | miRNA | Humans | Upregulated in PCa (log 2 fold change: 0.8817) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 31045265 |
1610 | mir-145 | miRNA | Humans | Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) | Prognostic | Gleason Score Upgradation Vs No Upgradation | p=0.03 | Tissue | 31045265 |
1611 | mir-221 | miRNA | Humans | Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129) | Prognostic | Biochemical recurrence Vs No Biochemical Recurrence | p=0.04 | Tissue | 31045265 |
1639 | miR-3162-5p | miRNA | Humans | NA | Prognostic | Gleason grades 4+5 and 5 Vs Gleason grade 4 | p=0.04 | Tissue | 31018918 |
1655 | miRâ€28; miRâ€100; miRâ€942; miRâ€28â€3p | miRNA | Humans | NA | Prognostic | Low Grade Vs High Grade Prostate Cancer | miRâ€28: p=0.016; miRâ€100: p=0.025; miRâ€942: p=0.025; miRâ€28â€3p: p=0.038 | Plasma | 30958910 |
1656 | miRâ€708; miRâ€1298; miRâ€886â€3p; miRâ€374; miRâ€376c; miRâ€202; miRâ€128a; miRâ€185 | miRNA | Humans | NA | Prognostic | Low Grade Vs High Grade Prostate Cancer | miRâ€708: p<0.001; miRâ€1298: p=0.001; miRâ€886â€3p:p=0.01; miRâ€374:p=0.017; miRâ€376c: p=0.031; miRâ€202: p=0.035; miRâ€128a: p=0.039; miRâ€185: p=0.041 | Plasma | 30958910 |
1697 | hsa-miR-518a | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p< 0.001 | Urine | 26126436 |
1698 | hsa-miR-3605 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p=0.033 | Urine | 26126436 |
1699 | hsa-miR-16 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p=0.04 | Urine | 26126436 |
1700 | RUN6-2 | miRNA | Humans | Downregulated in PCa (BPH: 4098.6; PCa: 2670.6) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p< 0.001 | Urine | 26126436 |
1701 | hsa-miR-615-3p | miRNA | Humans | Downregulated in PCa (BPH: 8842.4; PCa: 2781.7) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p< 0.001 | Urine | 26126436 |
1702 | hsv1-miR-H18 | miRNA | Humans | Downregulated in PCa (BPH: 1030.7; PCa: 619.2) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p< 0.001 | Urine | 26126436 |
1703 | hsv2-miR-H9-5p | miRNA | Humans | Downregulated in PCa (BPH: 1030.7; PCa: 619.2) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p< 0.001 | Urine | 26126436 |
1704 | hsv1-miR-H18 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | Tissue, Urine: p<0.001; Serum: p=0.004 | Tissue+Urine+Serum | 26126436 |
1705 | hsv2-miR-H9-5p | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | Tissue, Urine: p<0.001; Serum: p=0.002 | Tissue+Urine+Serum | 26126436 |
1706 | hsa-miR-615-3p | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | Tissue: p<0.001; | Tissue+Urine+Serum | 26126436 |
1707 | hsa-miR-BARTA-4 | miRNA | Humans | Upregulated in PCa (Tissue, Serum, Urine) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | Tissue: p<0.001; | Tissue+Urine+Serum | 26126436 |
1708 | hsa-miR-4316 | miRNA | Humans | Upregulated in PCa (Tissue, Serum, Urine) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | Tissue: p<0.001; Urine: p=0.022 | Tissue+Urine+Serum | 26126436 |
1709 | hsv1-miR-H18 | miRNA | Humans | Upregulated in PCa (Tissue) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Tissue+Urine | 26126436 |
1710 | hsv2-miR-H9-5p | miRNA | Humans | Upregulated in PCa (Tissue) | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Tissue+Urine | 26126436 |
1725 | miR-24+miR-30c+ Methylation Status of CRIP3 | miRNA + DNA (Gene) | Humans | Increased in shorter BCR-free survival | Prognostic | Reclassification (Progression Vs No Progression) | Univariate: p=0.008; Multivariate: p=0.017 | Urine | 30777394 |
1731 | hsaâ€mirâ€891a; hsaâ€mirâ€892a; hsaâ€mirâ€1224; hsaâ€mirâ€93; hsaâ€mirâ€23c; hsaâ€mirâ€1251; hsaâ€mirâ€204; hsaâ€mirâ€323b; hsaâ€mirâ€200c; hsaâ€mirâ€96; | miRNA | Humans | Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1) | Diagnostic | Prostate Cancer Vs Normal Adjacent | p<0.05 | Tissue | 30286759 |
1747 | miR-1260 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p=0.00001 | Tissue | 30250996 |
1748 | miR-1274a | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p=0.00001 | Tissue | 30250996 |
1762 | miR-1825 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.001 | Serum | 30324582 |
1763 | miR-484 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.001 | Serum | 30324582 |
1764 | miR-205 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.001 | Serum | 30324582 |
1765 | miR-141 | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.001 | Serum | 30324582 |
1766 | let-7b | miRNA | Humans | Downregulated in PCa | Diagnostic | Prostate Cancer Vs No Prostate Cancer | p<0.001 | Serum | 30324582 |
1767 | miR-1825 | miRNA | Humans | Downregulated in PCa | Prognostic | Stage T1-T2 Vs Stage T3-T4 | p<0.05 | Serum | 30324582 |
1768 | let-7b | miRNA | Humans | Upregulated in PCa | Prognostic | Stage T1-T2 Vs Stage T3-T4 | p<0.05 | Serum | 30324582 |
1769 | miR-205 | miRNA | Humans | Downregulated in PCa | Prognostic | Bone Metastasis Vs No Bone Metastasis | p<0.05 | Serum | 30324582 |
1772 | miR-141 | miRNA | Humans | Upregulated in Bone Metastasis | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | NA | Blood | 30334974 |
1773 | tPSA+ hK2+ PCA3+ miR-141 | miRNA | Humans | NA | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | NA | Blood | 30334974 |
1849 | miR-30c-5p | miRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Urine | 30728149 |
1850 | miR- 222-3p*+ miR-24-3p+ miR-30c-5p | miRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Urine | 30728149 |
1851 | miR- 222-3p*+ miR-24-3p+ miR-30c-5p+PSA | miRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign prostatic hyperplasia | p<0.05 | Urine | 30728149 |
1852 | miR-425-5p | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.001 | Tissue | 30720162 |
1853 | miR-425-5p | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Adjacent Normal | p<0.001 | Cell Lines | 30720162 |
1854 | miR-424 | miRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p=0.043 | Tissue | 30345533 |
1855 | miR-572 | miRNA | Humans | Upregulated in PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p= 0.031 | Tissue | 30345533 |
1856 | miR-572+ miR-424 | miRNA | Humans | Upregulated in PC3 and DU145 | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p= 0.031 | Tissue | 30345533 |
1857 | miR-572+ miR-424+ miR-1 + miR133b | miRNA | Humans | Downregulated in Recurrent PCa | Prognostic | Biochemical Recurrence Vs No Biochemical Recurrence | p= 0.031 | Tissue | 30345533 |
1919 | miR-17* | miRNA | Humans | Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.040 | Serum | 25786615 |
1920 | miR-200b* | miRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.045 | Serum | 25786615 |
1921 | miR-210 | miRNA | Humans | Differentially Expressed | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.003 | Serum | 25786615 |
1922 | miR-297 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.27 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.031 | Serum | 25786615 |
1923 | miR-375 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.13 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.009 | Serum | 25786615 |
1924 | miR-501-3p | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.02 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.015 | Serum | 25786615 |
1925 | miR-551b | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.30 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.017 | Serum | 25786615 |
1926 | miR-562 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (14.66 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | p=0.01 | Serum | 25786615 |
1927 | miR-562+ miR-210 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.12 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | NA | Serum | 25786615 |
1928 | miR-562+ miR-210+ miR-501-3p | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (17.39 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | NA | Serum | 25786615 |
1929 | miR-562+ miR-210+ miR-501-3p+ miR-375 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.72 fold) | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | NA | Serum | 25786615 |
1930 | miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b | miRNA | Humans | Upregulated in PCa | Diagnostic | Prostate Cancer Vs Benign Prostatic hyperplasia | NA | Serum | 25786615 |
1931 | let-7a* | miRNA | Humans | Upregulated in PCa | Prognostic | Disseminated PCa VS Localised PCa | p=0.012 | Serum | 25786615 |
1932 | miR-200b* | miRNA | Humans | Upregulated in PCa | Prognostic | Disseminated PCa VS Localised PCa | p=0.028 | Serum | 25786615 |
1933 | miR-210 | miRNA | Humans | Upregulated in PCa | Prognostic | Disseminated PCa VS Localised PCa | p=0.01 | Serum | 25786615 |
1934 | miR-297 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | p=0.038 | Serum | 25786615 |
1935 | miR-375 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | p=0.014 | Serum | 25786615 |
1936 | miR-501-3p | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | p=0.028 | Serum | 25786615 |
1937 | miR-562 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | p=0.03 | Serum | 25786615 |
1938 | miR-616 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | p=0.05 | Serum | 25786615 |
1939 | let-7a*+ miR-210 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | NA | Serum | 25786615 |
1940 | let-7a*+ miR-210+ miR-562 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | NA | Serum | 25786615 |
1941 | let-7a*+ miR-210+ miR-562+ miR-616 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | NA | Serum | 25786615 |
1942 | let-7a*+ miR-210+ miR-562+ miR-616+ miR-297 | miRNA | Humans | Upregulated in PCa [mean PC/mean]: (2.34 fold) | Prognostic | Disseminated PCa VS Localised PCa | NA | Serum | 25786615 |